Loading
Life sciences · Journal article
Advanced Science · October 28, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
ABSTRACT Developing strategies that simultaneously overcome chemoresistance and immune suppression remains a major challenge for improving transarterial chemoembolization (TACE) in hepatocellular carcinoma (HCC). Inspired by clinically used CaCO 3 microspheres in TACE, we propose an “extracellular buffering‐intracellular metabolic disruption” strategy to precisely regulate lactate homeostasis for targeted therapy. Herein, we engineered multifunctional embolic microspheres (SDCa‐MSs) co‐loaded with calcium carbonate nanoparticles (CaNPs), syrosingopine (Syr), and doxorubicin (DOX) for TACE application. Within the acidic tumor microenvironment, SDCa‐MSs buffer extracellular acidity while disrupting intracellular lactate metabolism, thereby simultaneously remodeling extracellular and intracellular pH homeostasis. This coordinated regulation enhances DOX efficacy, induces calcium dyshomeostasis and immunogenic cell death, and ultimately stimulates robust antitumor immunity. In multiple murine HCC models, SDCa‐MSs markedly suppress tumor growth, remodel the tumor immune microenvironment, and synergistically enhance the therapeutic efficacy of anti‐PD‐L1 immunotherapy. By integrating metabolic regulation, chemotherapy, and immune activation into a single embolic platform, this work establishes an acid–base homeostasis‐regulating strategy for potentiating TACE and provides a conceptual framework for improving locoregional cancer immunotherapy.